Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quetiapine fumarate + risperidone
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The entry 'quetiapine fumarate + risperidone' refers to a comparative clinical evaluation of two atypical antipsychotic medications, quetiapine (Seroquel) and risperidone (Risperdal), specifically within the context of a Phase 4 study sponsored by AstraZeneca for the treatment of schizophrenia. Quetiapine fumarate is a dibenzothiazepine derivative that acts as an antagonist at a broad range of neurotransmitter receptors, including dopamine D2, serotonin 5-HT2A, histamine H1, and adrenergic alpha-1 and alpha-2 receptors; it also exhibits partial agonism at 5-HT1A receptors. Risperidone is a benzisoxazole derivative that functions as a potent combined serotonin 5-HT2A and dopamine D2 receptor antagonist. In clinical practice and trials, these agents are compared to assess relative efficacy in symptom reduction (e.g., PANSS scores) and their distinct safety profiles, such as quetiapine's lower risk of extrapyramidal symptoms and prolactin elevation compared to risperidone's higher potency and different metabolic impact.
- Brand names
- SeroquelRisperdalSeroquel XRRisperdal Consta
- Other names
- quetiapinerisperidonequetiapine fumarate
02
Targets
DRD4 (Dopamine D4 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HRH1 (Histamine H1 Receptor)ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on quetiapine fumarate + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quetiapine fumarate + risperidone.